2015
Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease
Ala A, Aliu E, Schilsky ML. Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease. Digestive Diseases And Sciences 2015, 60: 1433-1439. PMID: 25605552, PMCID: PMC4427615, DOI: 10.1007/s10620-014-3495-6.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedChelating AgentsDrug Administration ScheduleFemaleHepatolenticular DegenerationHumansMaleMedication AdherenceMiddle AgedPatient DropoutsPatient SatisfactionPilot ProjectsProspective StudiesSurveys and QuestionnairesTime FactorsTreatment OutcomeTrientineYoung AdultConceptsSingle daily doseWilson's diseaseDaily doseDaily treatment regimenStable Wilson's diseaseProspective pilot studyLiver synthetic functionSingle daily dosageEnd of treatmentResultsAll patientsMaintenance therapyTreatment regimenDaily dosageLifelong therapyLarge trialsZinc excretionUrine copperTreatment stoppageSide effectsTreatment efficacyTrientineTherapyPatientsPilot studyDisease
2013
Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study
Chung R, Gordon F, Curry M, Schiano T, Emre S, Corey K, Markmann J, Hertl M, Pomposelli J, Pomfret E, Florman S, Schilsky M, Broering T, Finberg R, Szabo G, Zamore P, Khettry U, Babcock G, Ambrosino D, Leav B, Leney M, Smith H, Molrine D. Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study. American Journal Of Transplantation 2013, 13: 1047-1054. PMID: 23356386, PMCID: PMC3618536, DOI: 10.1111/ajt.12083.Peer-Reviewed Original ResearchConceptsLiver transplantationHepatitis C virusViral reboundViral loadPlacebo-controlled pilot studyAntibody-treated groupDays of transplantResistance-associated variantsHCV genotype 1aHuman monoclonal antibodyAllograft infectionRibavirin therapyPlacebo groupActing antiviralsPlacebo treatmentMedian timeViral clearanceSingle infusionC virusHCV E2Median changeGenotype 1aLimited efficacyDay 1Day 3